Novo Nordisk wants obesity tablet to have same effect as injection
Novo Nordisk aspires to provide an anti-obesity tablet which is as effective as the equivalent semaglutide injection.
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN
Danish phamaceutical company Novo Nordisk plans for its obesity tablet to cause weight losses amounting to those generated when the molecule semaglutide is administered as an injection, according to Novo Nordisk Executive Vice President of Development, Martin Holst Lange.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk initiates trial with obesity-treating tablet
For subscribers
.jpg&w=384&q=75)
